Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 9/20 | 0.52 |
| ▸ | OPRM1 | P35372 | 8/20 | 0.52 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.48 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10092884 | 1.00 | OPRL1 (0.52) | OPRL1OPRM1OPRK1OPRD1 | |
| SCHEMBL648625 | 1.00 | OPRL1 (0.52) | OPRL1OPRM1OPRK1OPRD1 | |
| SCHEMBL648467 | 0.92 | OPRL1 (0.55) | OPRL1OPRM1OPRK1OPRD1 | |
| SCHEMBL648468 | 0.92 | OPRL1 (0.55) | OPRL1OPRM1OPRK1OPRD1 | |
| SCHEMBL648466 | 0.92 | OPRL1 (0.55) | OPRL1OPRM1OPRK1OPRD1 | |
| SCHEMBL646844 | 0.92 | OPRL1 (0.55) | OPRL1OPRM1OPRK1OPRD1 | |
| SCHEMBL647247 | 0.92 | OPRL1 (0.55) | OPRL1OPRM1OPRK1OPRD1 | |
| SCHEMBL647933 | 0.79 | OPRM1 (0.31) | OPRL1OPRM1OPRK1 | |
| SCHEMBL16494167 | 0.78 | OPRL1 (0.50) | OPRL1OPRM1OPRK1OPRD1 | |
| SCHEMBL16494165 | 0.78 | OPRL1 (0.50) | OPRL1OPRM1OPRK1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8119661-B2 | Piperidine derivatives and their use as muscarinic receptor modulators | ASTRAZENECA AB (SE) | 2012-02-21 | — | — | US | disclosed |
| US-8119661-B2 | Piperidine derivatives and their use as muscarinic receptor modulators | ASTRAZENECA AB (SE) | 2012-02-21 | — | — | US | disclosed |
| US-8119661-B2 | Piperidine derivatives and their use as muscarinic receptor modulators | ASTRAZENECA AB (SE) | 2012-02-21 | — | — | US | disclosed |
| EP-2197843-B1 | PIPERIDINE DERIVATIVES AS AGONISTS OF MUSCARINIC RECEPTORS | ASTRAZENECA AB (SE) | 2011-12-28 | — | — | EP | disclosed |
| EP-2197843-B1 | PIPERIDINE DERIVATIVES AS AGONISTS OF MUSCARINIC RECEPTORS | ASTRAZENECA AB (SE) | 2011-12-28 | — | — | EP | disclosed |
| EP-2197843-A1 | PIPERIDINE DERIVATIVES AS AGONISTS OF MUSCARINIC RECEPTORS | AstraZeneca AB (SE) | 2010-06-23 | — | — | EP | disclosed |
| WO-2009034380-A1 | PIPERIDINE DERIVATIVES AS AGONISTS OF MUSCARINIC RECEPTORS | ASTRAZENECA AB (SE) | 2009-03-19 | — | — | WO | disclosed |
| WO-2009034380-A1 | PIPERIDINE DERIVATIVES AS AGONISTS OF MUSCARINIC RECEPTORS | ASTRAZENECA AB (SE) | 2009-03-19 | — | — | WO | disclosed |
| US-20090076078-A1 | New compounds 966 | ASTRAZENECA AB (SE) | 2009-03-19 | — | — | US | disclosed |
| US-20090076078-A1 | New compounds 966 | ASTRAZENECA AB (SE) | 2009-03-19 | — | — | US | disclosed |
| US-20090076078-A1 | New compounds 966 | ASTRAZENECA AB (SE) | 2009-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090076078-A1 | New compounds 966 | OPRM1, OPRL1, OPRK1 | OPRL1 2/4885OPRM1 1/4885OPRK1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.